Loading…
Adlai Nortye Group Ltd.
Adlai Nortye Group Ltd. (ANL) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in Singapore, Singapore and has 109 employees. The company is worth $710.31M. Revenue was $5M in fiscal 2025. It reported a net loss of $35.53M. The share price is 36.1% below its 52-week high of $17.25. 4 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Steve Cohen (Point72 Asset Management), at $24.62M. In that quarter, 2 of them opened or added to the position. Over the last 30 days, company insiders sold $163.27K of its stock on the open market and bought none.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▼ -26.5% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 3 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Year-end price | $1.42 | $2.68 | $8.99 | |
| P/S | — | 34.1x | — | — |
| P/B | — | — | 11.7x | 13.3x |
| EPS | -$1.11 | -$1.62 | -$7.56 | |
| Profit margin | — | -710.56% | — | — |
| ROE | — | — |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| SANASana Biotechnology, Inc. | $2.37 | — | 4.6x | 0.00% | -152.87% | $709.48M |
| CTKBCytek Biosciences, Inc. | $5.43 | — | 2.2x | 0.00% | -23.04% | $705.81M |
| ANNXAnnexon, Inc. | $3.81 | — | 3.6x | 0.00% | -105.26% | $722.3M |
| GERNGeron Corp | $1.13 |
| -203.53% |
| -145.55% |
Median of the years shown; P/E years above 200x are left out.
| — |
| 3.3x |
| 0.00% |
| -28.28% |
| $725.99M |
| IVAInventiva S.A. | $2.94 | — | 10.5x | 0.00% | -989.05% | $694.49M |
| OBXObsidian Therapeutics, Inc. | $11.77 | — | — | 0.00% | — | $727.07M |